IL248671B - A peptide composition containing a mutant of ras peptide and a therapeutic agent - Google Patents
A peptide composition containing a mutant of ras peptide and a therapeutic agentInfo
- Publication number
- IL248671B IL248671B IL248671A IL24867116A IL248671B IL 248671 B IL248671 B IL 248671B IL 248671 A IL248671 A IL 248671A IL 24867116 A IL24867116 A IL 24867116A IL 248671 B IL248671 B IL 248671B
- Authority
- IL
- Israel
- Prior art keywords
- peptide
- chemotherapeutic agent
- mutant ras
- vaccine
- peptide vaccine
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229940127089 cytotoxic agent Drugs 0.000 title 1
- 229940023041 peptide vaccine Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14167265 | 2014-05-06 | ||
| PCT/EP2015/059861 WO2015169804A1 (en) | 2014-05-06 | 2015-05-05 | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL248671A0 IL248671A0 (en) | 2017-01-31 |
| IL248671B true IL248671B (en) | 2021-08-31 |
Family
ID=50679896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL248671A IL248671B (en) | 2014-05-06 | 2016-11-01 | A peptide composition containing a mutant of ras peptide and a therapeutic agent |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9757439B2 (enExample) |
| EP (1) | EP3140320B1 (enExample) |
| JP (2) | JP2017514847A (enExample) |
| KR (1) | KR20170002563A (enExample) |
| CN (1) | CN106414493A (enExample) |
| AU (1) | AU2015257774B2 (enExample) |
| BR (1) | BR112016025764A2 (enExample) |
| CA (1) | CA2947963A1 (enExample) |
| CL (1) | CL2016002794A1 (enExample) |
| DK (1) | DK3140320T3 (enExample) |
| ES (1) | ES2716923T3 (enExample) |
| IL (1) | IL248671B (enExample) |
| MX (1) | MX2016014414A (enExample) |
| RU (1) | RU2700929C2 (enExample) |
| SG (2) | SG11201608712PA (enExample) |
| WO (1) | WO2015169804A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9775892B2 (en) | 2013-12-09 | 2017-10-03 | Targovax Asa | Peptide mixture |
| RU2765874C2 (ru) | 2016-10-26 | 2022-02-04 | МОДЕРНАТиЭкс, ИНК. | Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения |
| EP3576780A1 (en) * | 2017-02-01 | 2019-12-11 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
| CN110709094A (zh) | 2017-02-03 | 2020-01-17 | 威斯康星州医药大学股份有限公司 | Kras肽疫苗组合物及其使用方法 |
| CA3103983A1 (en) | 2018-06-19 | 2019-12-26 | Biontech Us Inc. | Neoantigens and uses thereof |
| WO2020002650A1 (en) | 2018-06-29 | 2020-01-02 | Targovax Asa | A formulation |
| CN109550044B (zh) * | 2018-10-19 | 2022-05-03 | 杭州纽安津生物科技有限公司 | 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用 |
| CA3141084A1 (en) * | 2019-06-12 | 2020-12-17 | Vikram JUNEJA | Neoantigen compositions and uses thereof |
| CN113416241B (zh) * | 2020-04-09 | 2022-04-08 | 北京臻知医学科技有限责任公司 | 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒 |
| JP2023535981A (ja) * | 2020-07-29 | 2023-08-22 | スクイーズ バイオテクノロジーズ カンパニー | 有核細胞を使用して変異型Ｒａｓに対する免疫応答を刺激する方法 |
| CN116322752A (zh) * | 2020-07-29 | 2023-06-23 | Sqz生物技术公司 | 使用无核细胞刺激对突变体ras的免疫应答的方法 |
| JP2023550515A (ja) * | 2020-11-24 | 2023-12-01 | シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド | Ｒａｓ突然変異体エピトープペプチドおよびｒａｓ突然変異体を認識するｔ細胞受容体 |
| EP4423256A2 (en) * | 2021-10-28 | 2024-09-04 | Genentech, Inc. | Systems and methods to identify mhc-associated antigens for therapeutic intervention |
| EP4522192A2 (en) * | 2022-05-12 | 2025-03-19 | The Johns Hopkins University | Neoantigen vaccines for cancer prevention |
| WO2025103205A1 (en) * | 2023-11-15 | 2025-05-22 | Ck Life Sciences Development Limited | Pharmaceutical compositions and methods for preventing or treating kras-associated diseases or conditions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9103974D0 (en) | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
| GB2328689A (en) | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| NO309798B1 (no) * | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
| AU2003301021C1 (en) | 2002-12-16 | 2010-02-18 | Globelmmune, Inc. | Yeast-based vaccines as immunotherapy |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US9775892B2 (en) | 2013-12-09 | 2017-10-03 | Targovax Asa | Peptide mixture |
-
2015
- 2015-05-05 CN CN201580023165.3A patent/CN106414493A/zh active Pending
- 2015-05-05 DK DK15720986.7T patent/DK3140320T3/en active
- 2015-05-05 SG SG11201608712PA patent/SG11201608712PA/en unknown
- 2015-05-05 US US15/308,917 patent/US9757439B2/en not_active Expired - Fee Related
- 2015-05-05 KR KR1020167034070A patent/KR20170002563A/ko not_active Withdrawn
- 2015-05-05 EP EP15720986.7A patent/EP3140320B1/en not_active Revoked
- 2015-05-05 JP JP2016565676A patent/JP2017514847A/ja active Pending
- 2015-05-05 MX MX2016014414A patent/MX2016014414A/es unknown
- 2015-05-05 AU AU2015257774A patent/AU2015257774B2/en not_active Ceased
- 2015-05-05 SG SG10201809701TA patent/SG10201809701TA/en unknown
- 2015-05-05 CA CA2947963A patent/CA2947963A1/en not_active Abandoned
- 2015-05-05 BR BR112016025764-2A patent/BR112016025764A2/pt not_active IP Right Cessation
- 2015-05-05 WO PCT/EP2015/059861 patent/WO2015169804A1/en not_active Ceased
- 2015-05-05 RU RU2016147527A patent/RU2700929C2/ru active
- 2015-05-05 ES ES15720986T patent/ES2716923T3/es active Active
-
2016
- 2016-11-01 IL IL248671A patent/IL248671B/en unknown
- 2016-11-04 CL CL2016002794A patent/CL2016002794A1/es unknown
-
2020
- 2020-02-27 JP JP2020032081A patent/JP7304629B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016025764A2 (pt) | 2018-01-16 |
| JP2020100650A (ja) | 2020-07-02 |
| RU2016147527A3 (enExample) | 2019-01-21 |
| RU2700929C2 (ru) | 2019-09-24 |
| SG11201608712PA (en) | 2016-11-29 |
| JP7304629B2 (ja) | 2023-07-07 |
| CN106414493A (zh) | 2017-02-15 |
| ES2716923T3 (es) | 2019-06-18 |
| EP3140320B1 (en) | 2018-12-26 |
| CL2016002794A1 (es) | 2017-06-09 |
| MX2016014414A (es) | 2017-02-23 |
| AU2015257774A1 (en) | 2016-12-22 |
| WO2015169804A1 (en) | 2015-11-12 |
| IL248671A0 (en) | 2017-01-31 |
| JP2017514847A (ja) | 2017-06-08 |
| EP3140320A1 (en) | 2017-03-15 |
| US20170065694A1 (en) | 2017-03-09 |
| RU2016147527A (ru) | 2018-06-08 |
| US9757439B2 (en) | 2017-09-12 |
| DK3140320T3 (en) | 2019-04-15 |
| AU2015257774B2 (en) | 2018-12-20 |
| KR20170002563A (ko) | 2017-01-06 |
| SG10201809701TA (en) | 2018-12-28 |
| CA2947963A1 (en) | 2015-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL248671A0 (en) | A peptide composition containing a mutant of ras peptide and a therapeutic agent | |
| IL249186B (en) | Anti-cd20 glycoantibodies and their uses | |
| SG10202002593SA (en) | Activated bifidobacteria and methods of use thereof | |
| IL247014A0 (en) | 6-heteroaryloxy and 6-aryloxy-quinoline-2-carboxamides and their use | |
| PL3152226T3 (pl) | Modyfikowane cyklopentapeptydy i ich zastosowania | |
| IL248424B (en) | Neuroprotective substances and their uses | |
| IL287985A (en) | A peptide derived from koc1 and a component containing it | |
| ZA201805977B (en) | Mycobacteriophages capable of delivering auto-luminescent elements and uses thereof | |
| IL257335A (en) | A depdc1-derived peptide and a component containing it | |
| PT3519025T (pt) | Dispositivo de administração | |
| IL251289A0 (en) | New peptide derivatives and their use | |
| GB201403248D0 (en) | Contrast agent and applications thereof | |
| IL250235A0 (en) | A peptide derived from urlc10 and a component containing it | |
| IL250215B (en) | A peptide derived from cdca1 and a component containing it | |
| PT3438118T (pt) | Derivado de peptídeo e utilização deste | |
| PL3307080T3 (pl) | Środek słodzący oraz jego zastosowanie | |
| SG11201610918RA (en) | Peptides and uses thereof | |
| GB201401673D0 (en) | Esculentin-2CHa peptide and analogues thereof | |
| IL247448A0 (en) | Peptides and methods of use | |
| PL3094338T3 (pl) | Oznaczenie i lek | |
| GB2545167B (en) | Cloches and use thereof | |
| PL3229772T3 (pl) | 6-arylo-9-glikozylopuryny i ich zastosowanie |